January/February 2018 Newsletter
|
|
In this issue:
- President's Message
- Regulatory Updates
- Board Update: Meetings Report
- R & E Update: MSHP R&E Foundation Nominations & Submissions
- Best Practice Spotlight: Get Fit with ENFit
- Affiliate Chapter News & Events
- UMKC SSHP Chapter Update: Fall Semester 2017
- Preceptor Development: MSHP Fall Meeting Highlights
- Featured Clinical Topics: Endocrinology
- Sodium-glucose Co-transporter 2 Inhibitors & Associated Cardiovascular Outcomes
- Latent Autoimmune Diabetes of Adults
- Management of Diabetic Ketoacidosis in Critically Ill Patients
- Subcutaneous Administration of Testosterone as an Alternative to Intramuscular Injection
- Going GLP-1
- Best Practice Spotlight: Residency Program Applications & Interviews
- Pharmacist Continuing Education
|
|
|
|
Happy 2018! The holidays are over and we’ve just embarked on another 67,000 mph orbit around the Sun, which means it’s time for MSHP get back to work! Throughout 2017, the amazing volunteers of MSHP had the opportunity to collaborate with the Missouri Legislature and the Board of Pharmacy to review our existing pharmacy rules and statutes.
|
|
|
|
The MSHP Public Policy Committee has been receiving monthly reports from the Hospital Advisory Committee (HAC). The following information was submitted by Greg Teale, on behalf of the HAC:
|
|
Board Update: Meetings Report
|
|
The MSHP board is in the process of reviewing and updating all of our policies and plan to have all polices updated this year.
|
|
|
MSHP R&E Foundation is currently accepting submissions and nominees for several awards. The deadline for all submissions and nominations will be
March 16, 2018.
|
|
Best Practice Spotlight:
Get Fit with ENFit
|
|
Make it your New Year’s resolution to pump up your pharmacy muscles by learning about the new enteral connections standards, ENFit®. A new novel enteral tubing system called ENFit® was designed to make enteral tubing and supplies incompatible with other traditional luer lock systems. The Joint Commission previously reported over 100 errors and 21 deaths have been attributed to the administration of enteral nutrition through intravenous lines.
1
To prevent these errors from occurring, the Global Enteral Device Supplier Association (GEDSA), a nonprofit trade association, was formed to establish a voice for addressing issues that face manufacturers, suppliers and distributors and to facilitate communication to healthcare facilities across the globe on enteral tubing changes through the Stay Connected 2014 initiative.
2
|
|
Affiliate Chapter News & Events
|
|
Greater Kansas City Society of Health-System Pharmacists (GKCSHP)
Upcoming Events:
February 15th, 2018
:
Topic:
Clinical Considerations in Neuromuscular Blockade Management, Location: Plaza III Steakhouse
Social Hour: 6:00-6:30 pm
Presentation: 6:30 pm
RSVP: at Capacity
March 22nd, 2018
:
Topic
TBD, Location TBD
Social Hour: 6:00-6:30 pm
Presentation: 6:30 pm
Location: TBD
GKCSHP is on Instagram! Follow us
@gkcshp
!
|
|
Mid-Missouri Society of Health-System Pharmacists (MMSHP)
Upcoming Events:
February 10th, 2018
:
Ronald McDonald House Service Project
, 8:30-11 am
March 1st, 2018
: Understanding the Non-interchangeability of Botulinum Toxins, Time: 6:30pm – appetizers and socializing, 7:00pm – dinner and presentation
Location: 44 Stone Public House (3910 Peachtree Dr. Columbia, MO)
March 8th, 2018
:
Pfizer Presentation
, Time and Location TBD
April 5th, 2018
:
GSK Vaccines
, Time and Location TBD
April 12th, 2018
:
MU Resident Presentations
, Time TBD at Shakespeare’s South
May 2018
:
UCB Presentation
, Time and Location TBD
|
|
Saint Louis Society of Health-System Pharmacists (StLSHP)
Upcoming Events:
February 15th, 2018
:
Topic:
Cresemba, Location: Surf & Sirloin
Social Hour: 6:30-7:00 pm
NOTE: Due to prescribing restrictions, providers that practice in a pediatric setting will be unable to attend this dinner.
|
|
UMKC SSHP Chapter Update:
Fall Semester 2017
|
|
At the beginning of the fall semester, SSHP held a membership drive from August to October 2nd. We recruited members through a poster at orientation for the first-year pharmacy students and at an event called "lunch on the lawn" for all pharmacy students.
|
|
Preceptor Development:
MSHP Fall Meeting Highlights
|
|
Teamwork Makes the Dream Work: Developing Collaborative Experiential Rotation Activities
Collaborative learning activities involving multiple preceptors and students, within and between institutions, provide benefits to all involved. Due to increased precepting and clinical service demands, preceptors have difficulty incorporating learning activities into introductory/advanced pharmacy practice experiences (IPPE/APPEs).
|
|
Featured Clinical Topic:
Endocrinology
|
|
Sodium-glucose Co-transporter 2 Inhibitors & Associated Cardiovascular Outcomes
|
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with diabetes.1,2 In fact, patients with type 2 diabetes are at least two times more likely to die from cardiovascular causes than the general population.
|
|
Latent Autoimmune Diabetes of Adults
|
Latent autoimmune diabetes of adults (LADA) is an intricate subset of diabetes that is complex and difficult to diagnosis. The American Diabetes Association (ADA) does not specify LADA as a separate diagnostic entity with confirmed treatments. As a result, the exact prevalence of LADA is unknown. However, 10% of patients in the United Kingdom Prospective Diabetes Study (UKPDS) trial most likely met criteria for LADA, totaling around 500 patients.
1
|
|
Management of Diabetic Ketoacidosis in Critically Ill Patients
|
It is estimated that patients with diabetes are more likely to be hospitalized and experience longer hospital stays than those without diabetes.
1
Additionally, severe hyperglycemia can lead to either diabetic ketoacidosis (DKA) and/or hyperosmolar hyperglycemic state (HHS), which are two of the most serious acute complications of diabetes associated with significant morbidity and mortality. Diabetic ketoacidosis is an acute complication of diabetes, responsible for over 500,000 hospital stays per year.
2
The remainder of this paper will be focused on the management of DKA.
|
|
Subcutaneous Administration of Testosterone as an Alternative to Intramuscular Injection
|
Subcutaneous (SC) testosterone is a novel delivery method that may alleviate concerns associated with intramuscular injections, improving adherence and patient attitude towards therapy. Intramuscular (IM) testosterone injections are often reported to cause pain, bruising, and a need to schedule injections with a healthcare provider if unable to self-administer.
1
IM injections often result in supraphysiologic levels of testosterone, followed by subtherapeutic troughs. This fluctuation in hormone levels can lead to an undesirable variability in mood, energy, and libido.
|
|
Since the first-in-class approval in 2005, there have been more glucagon-like peptide-1 (GLP-1) receptor agonists approved for type 2 diabetes mellitus (T2DM) than any other noninsulin monotherapy agent.
1
These agents provide clinicians more options in the diabetes armamentarium to individualize their patients’ regimens to meet individualized short-term and long-term goals. According the American Diabetes Association, a GLP-1 may be added if noninsulin monotherapy failed to help patients reach their A1c target.
2
Alternatively, practitioners may also need an additional agent for glycemic control after basal insulin has been maximized. Should a clinician decide to use a GLP-1, it is important to know how either short-acting (SA-GLP-1) or long-acting (LA-GLP-1) agonist subgroups can help a patient reach their goals, with an understanding of each agent’s pharmacokinetic profiles and clinical trial data.
|
|
Pharmacist Continuing Education
|
|
Initial Combination versus Monotherapy for the Treatment of Type 2 Diabetes
Program Number
: 2017-12-11
Approval Dates:
2/7/2018 to 5/6/2018
Approved Contact Hours
: One (1) CE(s) per LIVE session.
Submit answers for CE credit using the link below.
|
|
The Role of Non-Insulin Therapies in the Treatment of Type 1 Diabetes
Program Number:
2017-12-09
Approval Dates:
2/7/2018 to 5/6/2018
Approved Contact Hours:
One (1) CE(s) per LIVE session.
Submit answers for CE credit using the link below.
|
|
2018 MSHP/KCHP Spring Meeting
|
|
Call for Poster Abstracts
It is time for the 2018 Spring Meeting and poster submissions. If you have a poster that falls in to the following categories, please submit them.
Original Research:
To be considered for acceptance, papers must describe original research in pharmacotherapeutics, clinical pharmacokinetics, pharmacodynamics, practice innovations in organized health-care settings, administrative practice or cost analysis of pharmaceutical services. Papers must not have been published or presented elsewhere in complete form prior to presentation at the 2018 KCHP/MSHP Spring Meeting, with the exception of resident or student research presentations at the ASHP MCM.
Original research may be submitted as
research in progress
. Those abstracts submitted as research in progress are expected to have results and conclusions available for poster presentation at the Spring Meeting. Those with no results and conclusions submitted prior to the meeting are disqualified from award consideration.
Original research or research in progress may be submitted by a
pharmacist, pharmacy technician, resident, or student
. If a resident or student is listed as the submitting author for an original presentation, the poster will be eligible for the resident or student poster award. All other submitting authors will be eligible for the best original poster award.
Encore Research: This category is for research that has been presented elsewhere or published in complete form prior to presentation at the 2018 KCHP/MSHP Spring Meeting. To be considered for acceptance, papers must describe research in pharmacotherapeutics, clinical pharmacokinetics, pharmacodynamics, practice innovations in organized health-care settings, administrative practice or cost analysis of pharmaceutical services. Posters or papers presented before January 1 of the previous year are not eligible. For example, posters or papers presented before January 1, 2017 are not eligible for 2018 submissions. Full results and conclusions must have been presented/published previously to qualify as an encore presentation. Those projects previously presented/published without results and conclusions should be submitted as an original poster.
Encore research may be submitted by a
pharmacist, pharmacy technician, resident, or student
. Residents or students who presented their research only at the ASHP MCM may submit in the Original Research category.
**Case reports and literature reviews are not eligible for poster submission. These types of research may be eligible for submission to MSHP's Newsletter.
Poster Abstract Deadline is March 16, 2018
|
|
March/April 2018 Newsletter
Featured Clinical Topic:
Psychiatry
(we are at capacity)
Submission Deadline:
March 12, 2018
|
2018 Featured Clinical Topics
May/Jun: Critical Care
(we are at capacity)
/Pulmonary/Emergency Medicine
Jul/Aug: Pain
Sept/Oct: Cardiology/Anticoagulation
Nov/Dec: Infectious Disease
We are no longer accepting topics for the psychiatry and critical care featured articles, as they are at capacity
|
Newsletter Submission Guidelines
- Pharmacists, pharmacy technicians, and pharmacy students in Missouri are eligible to submit content for publication in the MSHP Newsletter. Student submissions need to include pharmacist oversight.
- Submit content to the current Newsletter Committee Chair on or before the established deadlines.
- CE and Featured Clinical Topics must be approved by the Newsletter Committee Chair in advance of article submission, to prevent duplicates. Duplicate articles submitted without advanced approval may not be published.
- Recommended length of submissions for committee, affiliate, college/schools of pharmacy, and student chapter reports is half to one page in length.
- Recommend length of submissions for featured clinical topics is 1 to 2 pages, without references.
- Recommended length of CE articles is individualized, based on the amount of CE provided.
- Recommended length of submission for other categories is 1 to 2 pages.
|
Newsletter Submission Deadlines
- Mar/Apr 2018: March 12th
- May/Jun 2018: May 14th
- Jul/Aug 2018: July 9th
- Sept/Oct 2018: September 10th
- Nov/Dec 2018: November 12th
|
|
Is there a Pharmacy Best Practice happening at your institution? Would you like to share your successes with MSHP Membership? We'd love to highlight your institution in a future MSHP Newsletter!
|
|
Interested in becoming a MSHP member or need to renew? It's easy! Click the above button or visit the MSHP website:
www.moshp.org/join-us.
Membership Dues:
Pharmacist: $110
Joint Pharmacist: (Husband/Wife) $155
Technician: $35
Associate Member: $110
Recent Graduate (within 24 months): $45
Student: $25
Retired Pharmacist: $35
|
|
MSHP Board of Directors
2017 - 2018
|
|
MSHP Committee Chairs
2017 - 2018
|
|
If you have any questions, comments, or wish to submit an article to for MSHP Newsletter, please contact the Newsletter Committee Chair:
Barb Kasper
or another Newsletter Committee member.
2017-2018 MSHP Newsletter Committee Members
|
|
|
|
|
|
|
